Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma

被引：24
作者：
Girgis, Suzette [1 ,3 ]
Lin, Shun Xin Wang [1 ]
Pillarisetti, Kodandaram [1 ]
Verona, Raluca [1 ]
Vieyra, Diego [1 ]
Casneuf, Tineke [2 ]
Fink, Damien [1 ]
Miao, Xin [1 ]
Chen, Yang [1 ]
Stephenson, Tara [1 ]
Banerjee, Arnob [1 ]
Hilder, Brandi W. [1 ]
Russell, Jeffery [1 ]
Infante, Jeffrey [1 ]
Elsayed, Yusri [1 ]
Smit, Jennifer [1 ]
Goldberg, Jenna D. [1 ]
机构：
[1] Janssen Res & Dev LLC, Spring House, PA USA
[2] Janssen Res & Dev LLC, Beerse, Belgium
[3] Janssen Res & Dev, 920 Route 202, Raritan, NJ 08869 USA
来源：
BLOOD ADVANCES | 2023年 / 7卷 / 04期
关键词：
CELL MATURATION ANTIGEN; BONE-MARROW; SURVIVAL;
D O I：
10.1182/bloodadvances.2022007625
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：644 / 648
页数：5
相关论文
共 50 条
  • [41] Bortezomib and dexamethasone for Japanese patients with relapsed and refractory multiple myeloma: a single center experience
    Igarashi, Natsue
    Chou, Takaaki
    Hirose, Takayuki
    Imai, Yousuke
    Ishiguro, Takuro
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2010, 92 (03) : 518 - 523
  • [42] Real World Treatment of Patients with Relapsed/Refractory Myeloma
    Dimopoulos, Meletios A.
    Ntanasis-Stathopoulos, Ioannis
    Terpos, Evangelos
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S24 - S27
  • [43] Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials
    Que, Yimei
    Xu, Menglei
    Xu, Yanjie
    Almeida, Varlene Daniela Fernandes
    Zhu, Li
    Wang, Zhiqiong
    Wang, Ying
    Liu, Xian
    Jiang, Lijun
    Wang, Di
    Li, Chunrui
    Zhou, Jianfeng
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [44] Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide
    Yee, Andrew J.
    Hari, Parameswaran
    Marcheselli, Raffaella
    Mahindra, Anuj K.
    Cirstea, Diana D.
    Scullen, Tyler A.
    Burke, Jill N.
    Rodig, Scott J.
    Hideshima, Teru
    Laubach, Jacob P.
    Ghobrial, Irene M.
    Schlossman, Robert L.
    Munshi, Nikhil C.
    Anderson, Kenneth C.
    Weller, Edie A.
    Richardson, Paul G.
    Raje, Noopur S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 166 (03) : 401 - 409
  • [45] Ibrutinib, lenalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma: Phase I trial results
    Ailawadhi, Sikander
    Parrondo, Ricardo D.
    Moustafa, Muhamad Alhaj
    LaPlant, Betsy R.
    Alegria, Victoria
    Chapin, Dustin
    Roy, Vivek
    Sher, Taimur
    Paulus, Aneel
    Chanan-Khan, Asher A.
    HEMATOLOGICAL ONCOLOGY, 2022, 40 (04) : 695 - 703
  • [46] Outcome of treatment with carfilzomib before and after treatment with daratumumab in relapsed or refractory multiple myeloma patients
    Hojholt, Karen Louise
    Gregersen, Henrik
    Szabo, Agoston Gyula
    Klausen, Tobias Wirenfeldt
    Levring, Mette Boegh
    Preiss, Birgitte
    Helleberg, Carsten
    Breinholt, Marie Fredslund
    Hermansen, Emil
    Rahbek Gjerdrum, Lise Mette
    Bonlokke, Soren Thorgaard
    Nielsen, Katrine
    Kjeldsen, Eigil
    Iversen, Katrine Fladeland
    Teodorescu, Elena Manuela
    Kurt, Eva
    Strandholdt, Casper
    Andersen, Mette Klarskov
    Vangsted, Annette Juul
    HEMATOLOGICAL ONCOLOGY, 2021, 39 (04) : 521 - 528
  • [47] Patient-Reported Factors in Treatment Satisfaction in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Chari, Ajai
    Romanus, Dorothy
    DasMahapatra, Pronabesh
    Hoole, Michael
    Lowe, Maria
    Curran, Chris
    Campbell, Scott
    Bell, Jill A.
    ONCOLOGIST, 2019, 24 (11) : 1479 - 1487
  • [48] Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma
    Bahlis, Nizar J.
    Sutherland, Heather
    White, Darrell
    Sebag, Michael
    Lentzsch, Suzanne
    Kotb, Rami
    Venner, Christopher P.
    Gasparetto, Cristina
    Del Col, Aldo
    Neri, Paola
    Reece, Donna
    Kauffman, Michael
    Shacham, Sharon
    Unger, T. J.
    Jeha, Jacqueline
    Saint-Martin, Jean-Richard
    Shah, Jatin
    Chen, Christine
    BLOOD, 2018, 132 (24) : 2546 - 2554
  • [49] Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma
    Facon, Thierry
    Niesvizky, Ruben
    Mateos, Maria-Victoria
    Siegel, David
    Rosenbaum, Cara
    Bringhen, Sara
    Weisel, Katja
    Ho, P. Joy
    Ludwig, Heinz
    Kumar, Shaji
    Wang, Kenneth
    Obreja, Mihaela
    Yang, Zhao
    Klippel, Zandra
    Mezzi, Khalid
    Goldrick, Amanda
    Tekle, Christina
    Dimopoulos, Meletios A.
    BLOOD ADVANCES, 2020, 4 (21) : 5449 - 5459
  • [50] Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: A phase 1/2 study
    Iida, Shinsuke
    Watanabe, Takashi
    Matsumoto, Morio
    Suzuki, Kenshi
    Sunami, Kazutaka
    Ishida, Tadao
    Ando, Kiyoshi
    Chou, Takaaki
    Ozaki, Shuji
    Taniwaki, Masafumi
    Uike, Naokuni
    Shibayama, Hirohiko
    Hatake, Kiyohiko
    Izutsu, Koji
    Ishikawa, Takayuki
    Shumiya, Yoshihisa
    Tobinai, Kensei
    CANCER SCIENCE, 2019, 110 (09) : 2924 - 2932
12345